Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03052166
Other study ID # BR005
Secondary ID
Status Completed
Phase
First received
Last updated
Start date April 18, 2017
Est. completion date January 1, 2020

Study information

Verified date March 2021
Source QT Ultrasound LLC
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Brief Summary: The QT Ultrasound system is an automated scanner which transmits pulsed ultrasound plane waves through the breast, as well as collects reflected ultrasound output. As the patient lays prone on a table, the breast is submerged in a warm water bath. The transmitter and receiver assembly moves around the suspended breast to record data for successive sub-volumes of targeted tissue. More than 2000 elements in the curvilinear transducer's array encircle the breast to gather data from the tissue structures of the breast, from nipple to chest wall. Information gathered from this automated QT scan encompasses the entire breast which is currently not commercially available using any other ultrasound technology.


Description:

This is a prospective, multicenter, multi-arm case collection study, with IRB approval. The study will follow an adaptive design with an initially planned total enrollment of approximately 600 cases to include both benign and malignant cases, representative of all tissue densities. The images and clinical data accrued in this prospective case collection will be used for creation of a database to facilitate future reader's studies, publications, building teaching files, and future marketing for QT Ultrasound.


Recruitment information / eligibility

Status Completed
Enrollment 755
Est. completion date January 1, 2020
Est. primary completion date December 31, 2019
Accepts healthy volunteers
Gender Female
Age group 18 Years and older
Eligibility INCLUSION CRITERIA All Subjects 1. Female 2. Age 18 or older 3. Willing to receive a QT Ultrasound Breast Scan 4. Willing and able to provide written Informed Consent prior to any research-related procedure(s) Cohort A and B Subjects that do not meet these Inclusion Criteria will be evaluated for Inclusion in Cohort C 1. Eligible for routine screening mammography as per ACR guidelines 2. Willing and able to submit or complete at the clinical site a Digital Mammography with Digital Breast Tomosynthesis exam (to include Craniocaudal (CC) and Mediolateral Oblique (MLO) views - for one or both breasts, within 3 months, before or after, their QT scan. Cohort C 1. Willing and able to submit available breast imaging - for one or both breasts, before or after, their QT scan. EXCLUSION CRITERIA All Subjects 1. Pregnancy 2. Currently breastfeeding 3. Allergies to device materials 4. Physical inability to tolerate the procedure on the scanner, i.e. inability to lie prone and still for up to 30 minutes at a time 5. Open wounds, sores or skin rash present on the breast(s) or nipple discharge from the scanned breast 6. Breasts too large for scanner, i.e. inability to successfully "fit" breast after the subject is placed on scanner 7. Body weight greater than 400 lbs. (180 kg) 8. Has a concurrent disease or condition which in the judgment of the Principal Investigator disqualifies the subject, from participating in the study 9. Magnetic material in the chest which in the judgement of the Principal Investigator would interfere with or be impacted by the magnets within the study device. Cohort A and B Subjects that meet any of these conditions below will not be eligible for Cohort A or B and will be evaluated for eligibility in Cohort C. 1. History of breast cancer in the past 12 months. 2. Most recent screening mammography exam was completed more than 3 months but less than 11 months prior. 3. History of breast surgeries or interventional breast procedures in the past 12 months, except for Fine Needle Aspiration(s) or Cyst Aspiration(s)

Study Design


Related Conditions & MeSH terms


Intervention

Device:
QT Ultrasound scan
QT Ultrasound scan

Locations

Country Name City State
United States Memorial Care Long Beach Long Beach California
United States Marin Breast Health Trial Center Novato California

Sponsors (1)

Lead Sponsor Collaborator
QT Ultrasound LLC

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Comparison of QT Ultrasound to DM-DBT Non-inferiority evaluation of sensitivity, specificity, positive predictive value and non-cancer recall rate. 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT04333706 - A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER) Phase 1/Phase 2
Active, not recruiting NCT05016310 - A Study of High-Dose Vit D Versus Standard of Care Vit D Supplementation N/A
Completed NCT00026689 - Evaluation for NCI Radiation Oncology Branch Clinical Research Protocols
Active, not recruiting NCT04715802 - Options on the Breast Reconstruction Timing and Method After Removal of Polyacrylamide Hydrogel
Recruiting NCT05720039 - Robotic vs. Open NSM for Early Stage Breast Cancer N/A
Recruiting NCT06157879 - Measuring Electrical Properties of Breast Tissues N/A
Completed NCT00277069 - Phase I-II Study of Carboplatin, Vinorelbine and Capecitabine in Patients With Metastatic Breast Cancer Phase 1/Phase 2
Recruiting NCT06083415 - Early Breast Growth in Girls Aged 6 to 8 Years in the Current Environmental Context N/A
Active, not recruiting NCT02734004 - A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. Phase 1/Phase 2
Recruiting NCT03047122 - Detection of Breast Lesions by Automatic Breast US N/A
Withdrawn NCT01114984 - Post-Breast Procedure Pain Syndrome Study N/A
Recruiting NCT05290402 - Development of an Application-Based Digital Navigator for Perioperative Breast Surgery Patients
Active, not recruiting NCT01078662 - Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats Phase 2
Not yet recruiting NCT05663801 - Magnesium Sulphate Versus Ketamine as an Adjuvant to Bupivacaine in Pectoral Nerve Block During Mastectomy Phase 2
Terminated NCT00277004 - Physiological Biomarkers of Cancer Treatment Related Fatigue in Women With Breast Cancer.
Completed NCT04524728 - Patterns of Treatment and Outcome of Palbociclib Plus Endocrine Therapy
Withdrawn NCT00845078 - Prospective Outcomes After Reconstruction and Radiotherapy for Breast Cancer N/A
Completed NCT00972205 - Paclitaxel and CBT-1(Registered Trademark) to Treat Solid Tumors N/A
Recruiting NCT04174742 - Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer
Completed NCT00064857 - Pycnogenol for the Treatment of Lymphedema of the Arm in Breast Cancer Survivors Phase 2